Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Linden

Showing results (391-400 of 409) with videos related to

Pageof 41
Sort By:
Molecular Imaging and Biology|May 14, 2025
[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast CancerPoorni M Manohar, Lanell M Peterson, Isaac C Jenkins, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2018
Prospective Study of Serial <sup>18</sup>F-FDG PET and <sup>18</sup>F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast CancerLanell M Peterson, Janet O'Sullivan, Qian Vicky Wu, et al.
American Journal of Clinical Oncology|September 19, 2023
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) DatabaseBonny Chau, Elizabeth T Loggers, Lee D Cranmer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 28, 2020
<sup>18</sup>F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast CancerLanell M Peterson, Brenda F Kurland, Fengting Yan, et al.
Breast Cancer Research : BCR|August 24, 2021
<sup>18</sup>F-fluorodeoxyglucose (FDG) PET or <sup>18</sup>F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity studyPerrin E Romine, Lanell M Peterson, Brenda F Kurland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancerHannah M Linden, Brenda F Kurland, Lanell M Peterson, et al.
Journal of Dairy Science|September 16, 2019
Genetic selection for bovine chromosome 18 haplotypes associated with divergent somatic cell score affects postpartum reproductive and metabolic performanceM M Meyerholz, L Rohmeier, T Eickhoff, et al.
Nature Communications|July 15, 2022
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancerAditya Bardia, Sarat Chandarlapaty, Hannah M Linden, et al.
Clinical Breast Cancer|June 23, 2021
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast CancerLynn Symonds, Isaac Jenkins, Hannah M Linden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trialsJames M Mountz, Thomas E Yankeelov, Daniel L Rubin, et al.
Pageof 41

Showing results (391-400 of 409) with videos related to

Sort By:
Pageof 41
Molecular Imaging and Biology|May 14, 2025
[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast CancerPoorni M Manohar, Lanell M Peterson, Isaac C Jenkins, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2018
Prospective Study of Serial <sup>18</sup>F-FDG PET and <sup>18</sup>F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast CancerLanell M Peterson, Janet O'Sullivan, Qian Vicky Wu, et al.
American Journal of Clinical Oncology|September 19, 2023
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) DatabaseBonny Chau, Elizabeth T Loggers, Lee D Cranmer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 28, 2020
<sup>18</sup>F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast CancerLanell M Peterson, Brenda F Kurland, Fengting Yan, et al.
Breast Cancer Research : BCR|August 24, 2021
<sup>18</sup>F-fluorodeoxyglucose (FDG) PET or <sup>18</sup>F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity studyPerrin E Romine, Lanell M Peterson, Brenda F Kurland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancerHannah M Linden, Brenda F Kurland, Lanell M Peterson, et al.
Journal of Dairy Science|September 16, 2019
Genetic selection for bovine chromosome 18 haplotypes associated with divergent somatic cell score affects postpartum reproductive and metabolic performanceM M Meyerholz, L Rohmeier, T Eickhoff, et al.
Nature Communications|July 15, 2022
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancerAditya Bardia, Sarat Chandarlapaty, Hannah M Linden, et al.
Clinical Breast Cancer|June 23, 2021
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast CancerLynn Symonds, Isaac Jenkins, Hannah M Linden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trialsJames M Mountz, Thomas E Yankeelov, Daniel L Rubin, et al.
Pageof 41